- 期刊
癌症免疫治療的不良反應與處置
The Management of Immune Related Adverse Events Associated with Cancer Immunotherapy
摘要
1982年起惡性腫瘤高居台灣十大死因首位，每年會奪走4萬多人的性命，且癌症發生率節節高升，面對高死亡率及高發生率的癌症，近年來，其相關的治療也日新月異，從化學治療、標靶治療，自2010年後更進一步發展到免疫治療，除所費不貲外，相關的副作用也和傳統治療大不相同，免疫治療的副作用統稱為免疫相關不良反應（immune-related adverse events, irAEs），可能影響全身的器官或組織，甚至有致命的威脅。因此，醫護人員應密切監測及追蹤病人的免疫相關不良反應，藉以早期鑑別不良反應的程度分級，並依據處置重點進行治療，期望能使癌症免疫治療達到最大療效。
並列摘要
In Taiwan, malignant neoplasms have ranked top ten causes of death since 1982, claiming the lives of more than 40,000 people each year. As the incidence of cancer rises steadily carrying high mortality in recent years, relevant treatments are also seen changing almost from day to day and from chemotherapy to target therapy, then evolving further to cancer immunotherapy in 2010. Apart from the fact that immunotherapy is very costly, the related side effects, far from those of the traditional treatments, are also an eyebrow raiser. The side effects of immunotherapy are collectively referred to as Immune-related adverse events (irAEs), which may affect organs or tissues throughout the body, or even present a fatal threat. Therefore, health care professionals should closely monitor and follow up on patients' immune-related adverse events in order to early identify the adverse events and to evaluate the level of response so further treatment can be planned according to achieve the maximum expected effect from the cancer immunotherapy.